Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
Obstructive Lung Disease
•
COPD
Have you implemented the Rome proposal for COPD exacerbations?
Related Questions
Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
Did the low rate of COPD exacerbations in the BOREAS cohort overall confound the results of the study?
What patient factors prompt you to consider starting dupilumab in patients with COPD?
Are the results of the BOREAS trial generalizable to non-white populations?
Is there a role for biologics to improve lung function in patients who have severe asthma with daily symptoms and reduced lung function but do not experience frequent exacerbations?
Is methacholine challenge on its way out?
What is your approach to inhaler therapy in a patient with asthma who cannot be on an inhaled corticosteroid due to ocular disease?
What factors do you consider prior to offering a trial of ICS/LABA therapy versus a methacholine challenge test in patients with suspected asthma but normal pulmonary function testing?
Do you prescribe bronchodilators to patients with radiographic emphysema and respiratory symptoms, but no spirometric obstruction?
Can recurrent bilateral nasal polyps be attributed to untreated ABPA?
